|

FAK Inhibitor GSK2256098 Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 2: 1

Top Sponsors

  • Alliance for Clinical Trials in Oncology1

Indications

  • NF2 Gene Mutation1
  • Intracranial Meningioma1
  • Recurrent Meningioma1
  • Cancer1

Birmingham, Alabama1 trial

Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas

University of Alabama at Birmingham Cancer Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.